link
Bookmarks
RECIST
Brett W. Carter, MD
To access 4,300 diagnoses written by the world's leading experts in radiology, please log in or subscribe.Log inSubscribe

KEY FACTS

  • Terminology

    • Baseline Evaluation

      • Clinical Implications

        TERMINOLOGY

        • Abbreviations

          • Response Evaluation Criteria in Solid Tumors (RECIST)
        • Definitions

          • Response criteria published in 2000
          • Updated WHO criteria
            • Designed to minimize risk of measurement error and prevent overestimation of response rates
        • Rationale and Key Concepts

          • Patient eligibility
            • Patients with measurable disease at baseline
              • Measurable disease: Indicates presence of at least 1 measurable lesion
            • Enrolled in protocols where objective tumor response is primary endpoint
          • Assess disease at baseline
            • Evaluate for measurable disease
            • Identify target and nontarget lesions
            • Measure target lesions
            • Tumor burden: Sum of target lesions
          • Assess disease at follow-up
            • Measure target lesions
            • Assess nontarget lesions
            • Identify new lesions
            • Calculate time point response

        IMAGING ANATOMY

        • Measurable and Nonmeasurable Disease

          • Baseline Documentation

            • Methods of Assessment

              • Summary of Minimum Size Requirements for Measurable Lesions

                CLINICAL IMPLICATIONS

                • Evaluation of Target Lesions

                  • Evaluation of Nontarget Lesions

                    • Evaluation of Best Overall Response

                      • Confirmation of Response

                        Selected References

                        1. Gehan EA et al: Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)? J Natl Cancer Inst. 92(3):179-81, 2000
                        2. Kusaba H et al: A summary report of response evaluation criteria in solid tumors (RECIST criteria). Gan To Kagaku Ryoho. 27(1):1-5, 2000
                        3. Therasse P et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 92(3):205-16, 2000
                        Related Anatomy
                        Loading...
                        Related Differential Diagnoses
                        Loading...
                        References
                        Tables

                        Tables

                        KEY FACTS

                        • Terminology

                          • Baseline Evaluation

                            • Clinical Implications

                              TERMINOLOGY

                              • Abbreviations

                                • Response Evaluation Criteria in Solid Tumors (RECIST)
                              • Definitions

                                • Response criteria published in 2000
                                • Updated WHO criteria
                                  • Designed to minimize risk of measurement error and prevent overestimation of response rates
                              • Rationale and Key Concepts

                                • Patient eligibility
                                  • Patients with measurable disease at baseline
                                    • Measurable disease: Indicates presence of at least 1 measurable lesion
                                  • Enrolled in protocols where objective tumor response is primary endpoint
                                • Assess disease at baseline
                                  • Evaluate for measurable disease
                                  • Identify target and nontarget lesions
                                  • Measure target lesions
                                  • Tumor burden: Sum of target lesions
                                • Assess disease at follow-up
                                  • Measure target lesions
                                  • Assess nontarget lesions
                                  • Identify new lesions
                                  • Calculate time point response

                              IMAGING ANATOMY

                              • Measurable and Nonmeasurable Disease

                                • Baseline Documentation

                                  • Methods of Assessment

                                    • Summary of Minimum Size Requirements for Measurable Lesions

                                      CLINICAL IMPLICATIONS

                                      • Evaluation of Target Lesions

                                        • Evaluation of Nontarget Lesions

                                          • Evaluation of Best Overall Response

                                            • Confirmation of Response

                                              Selected References

                                              1. Gehan EA et al: Will there be resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)? J Natl Cancer Inst. 92(3):179-81, 2000
                                              2. Kusaba H et al: A summary report of response evaluation criteria in solid tumors (RECIST criteria). Gan To Kagaku Ryoho. 27(1):1-5, 2000
                                              3. Therasse P et al: New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst. 92(3):205-16, 2000